Agreement includes up to USD 1.4 billion with upfront and potential future milestone payments plus tiered royalties Novo will also make a strategic investment in Orbis Medicines Collaboration seeks to develop orally bioavailable macrocycle drug candidates for cardiometabolic targets Partnership combines Novo's leadership in obesity and cardiometabolic disease with Orbis Medicines' proprietary AI-enabled macrocycle discovery platform COPENHAGEN, Denmark, September 17, 2026--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.